Curocell CEO Kim Gun-soo, a bio-venture founded based on his father's experience battling illness, presented the process of developing Limcato, the first CAR-T therapy in Korea, and obtaining approval as the 42nd domestic new drug, as well as a vision for the future development of solid tumor treatments.
Curocell CEO Kim Gun-soo, a bio-venture founded based on his father's experience battling illness, presented the process of developing Limcato, the first CAR-T therapy in Korea, and obtaining approval as the 42nd domestic new drug, as well as a vision for the future development of solid tumor treatments.